Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors

Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors

(2021) Giovanni Fucà et al.   Journal for ImmunoTherapy of Cancer

SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

(2021) T. André et al.   ANNALS OF ONCOLOGY

The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors

(2021) Francesca Corti et al.   EUROPEAN JOURNAL OF CANCER

A phase III study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW.

(2020) Sandzhar Abdullaev et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.

(2020) Heinz-Josef Lenz et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610).

(2020) Caio Max Sao Pedro Rocha Lima et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer

(2020) Kaysia Ludford et al.   JNCI-Journal of the National Cancer Institute

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

(2020) Myriam Chalabi et al.   NATURE MEDICINE

Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability‐High End‐Stage Cancers and Poor Performance Status Related to High Disease Burden

(2020) Filippo Pietrantonio et al.   ONCOLOGIST

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

(2020) Caroline Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

(2020) Thierry André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

(2019) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach

(2019) C Luchini et al.   ANNALS OF ONCOLOGY

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

(2019) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Colorectal cancer

(2019) Evelien Dekker et al.   LANCET

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

(2018) E Dell’Aquila et al.   ANNALS OF ONCOLOGY

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients

(2016) K. Tada et al.   Cancer Immunology Research

Cure Models as a Useful Statistical Tool for Analyzing Survival

(2012) M. Othus et al.   CLINICAL CANCER RESEARCH

Random survival forests

(2008) Hemant Ishwaran et al.   Annals of Applied Statistics